Rua Bioscience Limited — Director's Dealing 2020

Oct 22, 2020

==> picture [103 x 28] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Date this disclosure made: Date on which issuer listed or appointment made:

Rua Bioscience Limited 22-Oct-20 22-Oct-20

Director or senior manager giving disclosure

Full name: Name of listed issuer: Name of related body corporate (if applicable): Position held in listed issuer:

Panapa Ehau Rua Bioscience Limited Director of Rua Bioscience Limited

Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product: Number held in class: Nature of relevant interest: Current registered holder:

Ordinary shares in Rua Bioscience Limited 252,293 Registered and beneficial holder Panapa Ehau

Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product: Number held in class: Nature of relevant interest: Current registered holder:

Ordinary shares in Rua Bioscience Limited 726 Director and shareholder of Waiapu Investments Limited ( WIL ). WIL is the registered holder and beneficial owner of 726 shares in Rua Bioscience Limited Waiapu Investments Limited

Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product: Number held in class: Nature of relevant interest: Current registered holder:

Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan 55,000 options potentially convertible to 283,072 ordinary shares

Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan N/A

Summary of relevant interest (excluding specified derivatives)

Class of quoted financial product: Number held in class:

Rights to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share bonus offer Right to 27,099 shares

Nature of relevant interest:

Current registered holder:

Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share bonus offer N/A

Details of derivative

The notional value of the derivative (if any) or the notional amount of underlying products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price specified in the terms of the derivative(if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A N/A N/A N/A N/A N/A N/A N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer: Date of signature:

==> picture [82 x 32] intentionally omitted <==

22-Oct-20

Name and title of authorised person:

==> picture [75 x 20] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		RuaBioscienceLimited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Rob Mitchell
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Chief Executive Officer of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		40,000
Nature of relevant interest:		Registered and beneficial holder
Current registered holder:		Rob Mitchell
Summary of relevant interest (excluding specified derivatives)
		Options that are convertible to
Class of quoted financial product:		ordinary shares in Rua Bioscience Limited under Rua Bioscience
		Limited's employee share option plan
Number held in class:		55,000 options potentially convertible to 301,453 ordinary shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share option plan
Current registered holder:		N/A
Summary of relevant interest (excluding specified derivatives)
		Rights to ordinary shares in Rua
Class of quoted financial product:		Bioscience Limited under Rua Bioscience Limited's employee share
		bonus offer
Number held in class:		Right to 70,320 shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share bonus offer
Current registered holder:		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlyingfinancialproducts:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

==> picture [86 x 24] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		Rua Bioscience Limited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Brett Gamble
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Director of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		1,536,123
Nature of relevant interest:		Director and 50% shareholder of Aoraki Holdings (No 2) Limited
Current registered holder:		Aoraki Holdings (No 2) Limited
Summary of relevant interest(excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		269,791
Nature of relevant interest:		Director and shareholder of Positano Holdings Limited
Current registered holder:		Positano Holdings Limited
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturitydate of the derivative(if any):		N/A
Expirydate of the derivative(if any):		N/A
Theprice specified in the terms of the derivative(if any):		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlyingfinancialproducts:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

==> picture [75 x 20] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		RuaBioscienceLimited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Paul Naske
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Chief Operating Officer of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		20,880
Nature of relevant interest:		Registered and beneficial holder
Current registered holder:		Paul Naske
Summary of relevant interest (excluding specified derivatives)
		Options that are convertible to
Class of quoted financial product:		ordinary shares in Rua Bioscience Limited under Rua Bioscience
		Limited's employee share option plan
Number held in class:		32,000 options potentially convertible to 164,696 ordinary shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share option plan
Current registered holder:		N/A
Summary of relevant interest (excluding specified derivatives)
		Rights to ordinary shares in Rua
Class of quoted financial product:		Bioscience Limited under Rua Bioscience Limited's employee share
		bonus offer
Number held in class:		Right to 26,058 shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share bonus offer
Current registered holder:		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlyingfinancialproducts:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

==> picture [94 x 26] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		Rua Bioscience Limited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Martin Smith
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Director of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		2,544,732
		Joint shareholder (in Martin's
Nature of relevant interest:		capacity as trustee of the Wakaroma
		Trust)
		Martin Smith, Aneta Bird and Sara
Current registered holder:		Maree Lunam as trustees of the
		WakaromaTrust
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturitydate of the derivative(if any):		N/A
Expirydate of the derivative(if any):		N/A
Theprice specified in the terms of the derivative(if any):		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlying financial products:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

==> picture [98 x 27] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		Rua Bioscience Limited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Anna Stove
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Director of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		763,896
Nature of relevant interest:		Registered and beneficial holder
Current registered holder:		Anna Stove
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturity date of the derivative (if any):		N/A
Expiry date of the derivative (if any):		N/A
The price specified in the terms of the derivative(if any):		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlying financial products:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

==> picture [83 x 22] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and Name of listed issuer: Date this disclosure made: Date on which issuer listed or appointment made: Director or senior manager giving disclosure Full name: Name of listed issuer: Name of related body corporate (if applicable): Position held in listed issuer: Summary of relevant interest (excluding specified derivatives) Class of quoted financial product: Number held in class: Nature of relevant interest: Current registered holder: Summary of relevant interest (excluding specified derivatives) Class of quoted financial product: Number held in class: Nature of relevant interest: Current registered holder: Details of derivative The notional value of the derivative (if any) or the notional amount of underlying products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price specified in the terms of the derivative(if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: Certification I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons Signature of director or officer: Date of signature: or Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

Rua Bioscience Limited 22-Oct-20 22-Oct-20 Trevor Burt Rua Bioscience Limited Breakaway Investments Limited Chairperson and director of Rua Bioscience Limited Ordinary shares in Rua Bioscience Limited 763,896 Shareholder and beneficial owner of Breakaway Investments Limited Breakaway Investments Limited Options that are convertible to ordinary shares in Rua Bioscience Limited under Rua Bioscience Limited's employee share option plan 55,000 options potentially convertible to 283,072 ordinary shares Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua Bioscience Limited's employee share option plan N/A N/A N/A N/A N/A N/A N/A N/A N/A 22-Oct-20

==> picture [67 x 19] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

==> picture [302 x 555] intentionally omitted <==

----- Start of picture text -----

To NZX Limited; and
Name of listed issuer: Rua Bioscience Limited
Date this disclosure made: 22-Oct-20
Date on which issuer listed or appointment made: 22-Oct-20
Director or senior manager giving disclosure
Full name: Manu Caddie
Name of listed issuer: Rua Bioscience Limited
Name of related body corporate (if applicable):
Kaihautu - Head of Innovation and
Position held in listed issuer: Regulation of Rua Bioscience
Limited
Summary of relevant interest (excluding specified derivatives)
Ordinary shares in Rua Bioscience
Class of quoted financial product: Limited
Number held in class: 9,395,515
Director and shareholder of New
Zealand Nutraceuticals Limited
( NZNL ). NZNL is a limited partner of
Hikurangi Bioactives Limited
Nature of relevant interest: Partnership ( HBLP ) with a 40%
economic interest in HBLP. HBLP is
the registered holder and beneficial
owner of 23,488,787 ordinary
shares in Rua Bioscience Limited
Current registered holder: HBLP
Summary of relevant interest (excluding specified derivatives)
Options that are convertible to
ordinary shares in Rua Bioscience
Class of quoted financial product: Limited under Rua Bioscience
Limited's employee share option
plan
55,000 options potentially
Number held in class: convertible to 283,072 ordinary
shares
Entitlement to become legal and
beneficial owner subject to the
Nature of relevant interest: meeting of vesting and other terms
and conditions under Rua
Bioscience Limited's employee
share option plan
Current registered holder: N/A
Details of derivative
The notional value of the derivative (if any) or the notional amount of underlying N/A
products (if any):
A statement as to whether the derivative is cash settled or physically settled: N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative(if any): N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the N/A
underlying financial products:
For that derivative,-
Parties to the derivative: N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative: N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature: 22-Oct-20
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
----- End of picture text -----

==> picture [75 x 20] intentionally omitted <==

Initial Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:		RuaBioscienceLimited
Date this disclosure made:		22-Oct-20
Date on which issuer listed or appointment made:		22-Oct-20
Director or senior manager giving disclosure
Full name:		Hamish White
Name of listed issuer:		Rua Bioscience Limited
Name of related bodycorporate(if applicable):
Position held in listed issuer:		Chief Financial Officer of Rua Bioscience Limited
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:		Ordinary shares in Rua Bioscience Limited
Number held in class:		99,990
Nature of relevant interest:		Registered and beneficial holder
Current registered holder:		Hamish White
Summary of relevant interest (excluding specified derivatives)
		Options that are convertible to
Class of quoted financial product:		ordinary shares in Rua Bioscience Limited under Rua Bioscience
		Limited's employee share option plan
Number held in class:		55,000 options potentially convertible to 283,072 ordinary shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share option plan
Current registered holder:		N/A
Summary of relevant interest (excluding specified derivatives)
		Rights to ordinary shares in Rua
Class of quoted financial product:		Bioscience Limited under Rua Bioscience Limited's employee share
		bonus offer
Number held in class:		Right to 26,058 shares
		Entitlement to become legal and
		beneficial owner subject to the
Nature of relevant interest:		meeting of vesting and other terms
		and conditions under Rua Bioscience
		Limited's employee share bonus offer
Current registered holder:		N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the		N/A
underlyingfinancialproducts:
For that derivative,-
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:		N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:		22-Oct-20
or
Signature ofperson authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: